Morgan Stanley Says CareFusion Corporation Management Meetings Support Improving Risk/Reward

In a report published Wednesday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on

. In the report, Morgan Stanley noted, “Management meetings support an improving risk/reward into FY15. Accelerating Pyxis momentum and a sustained commitment to capital deployment suggest medium term growth goals that imply ~$2.75-2.90 in FY15 EPS (vs. cons. $2.66) are still achievable.” CareFusion Corporation closed on Tuesday at $40.50.